Why the study?
Diuretic resistance in heart failure is associated with worse outcomes, but the efficacy of subcutaneous furosemide via on-body infusor in patients with diuretic resistance post-heart failure hospitalization was unknown.
Does single-dose subcutaneous furosemide improve diuretic efficiency and peak urine sodium compared to oral furosemide in patients with diuretic resistance post-heart failure hospitalization?
Does single-dose subcutaneous furosemide improve diuretic efficiency and peak urine sodium compared to oral furosemide in patients with diuretic resistance post-heart failure hospitalization?
Single-dose subcutaneous furosemide provides greater diuretic efficiency and peak urine sodium than oral furosemide in heart failure patients with diuretic resistance recently discharged from the hospital.
Answers are grounded in this paper and cite their sources.
May support sc over oral furosemide in diuretic-resistant HF post-discharge; extends limited RCT evidence on route efficacy.
AIMS: Diuretic resistance (DR) in heart failure (HF) is associated with worse outcomes. Furoscix®, a self-administered subcutaneous (sc) furosemide injection administered via on-body infusor, is approved for HF congestion relief. However, its efficacy in patients with DR post-HF hospitalization remains unknown. METHODS AND RESULTS: : treatment × diuretic resistance = 0.022). CONCLUSION: Single-dose sc furosemide was associated with greater diuretic efficiency and peak urine sodium than oral furosemide in participants with DR discharged following recent HF hospitalization.
No takes yet. Share an insight, caveat, or question.
Keshvani et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: